Philip Sager, MD
Enriched profileAdjunct Professor, Cardiovascular Institute Operations · Stanford University School of Medicine
Philip Sager is Adjunct Professor, Cardiovascular Institute Operations at Stanford University School of Medicine. OpenAlex indexes 192 publications with 11,378 citations (h-index 48); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Philip T. Sager, MD, is Adjunct Professor, Cardiovascular Institute Operations at Stanford University School of Medicine. The public record shows 192 publications with 11,378 citations (h-index 48), centered on Coronary Artery Disease / ACS. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 8 companies.
- Most recent indexed publication: 2024 · Clinical and translational science
- Top research focus: Coronary Artery Disease / ACS
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Former Chair (completed 5-year term)
FDA Cardiovascular and Renal Drugs Advisory Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - Voting Member
FDA Cardiovascular and Renal Drugs Advisory Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →crediblemeds.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
Industry payments
Updated 27 Aug 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20252 payments$139,305openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20254 payments$17,640openpaymentsdata.cms.gov ↗
- ACADIA Pharmaceuticals IncProgram year20251 payment
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- An overview of drug-induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety.
Clinical and translational science
Review2024 - Self-Administered Etripamil Nasal Spray Relieved Symptoms, Decreased Heart Rate, and Reduced Medical Interventions During Atrioventricular Nodal-Dependent Paroxysmal Supraventricular Tachycardia.
Circulation. Arrhythmia and electrophysiology
Letter2024 - Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.
Journal of the American Heart Association
Clinical Trial2023 - First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
Circulation. Arrhythmia and electrophysiology
Clinical Trial2022
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/philipsagermd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
med.stanford.edu/cvi/mission/news_center/articles_announcements/2010-2015/philipsager
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗ - Other
milestonepharma.com/leadership/philip-sager
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →milestonepharma.com ↗ - LinkedIn
LinkedIn: Philip Sager, MD, FACC, FAHA, FHRS - Sager Consulting Experts
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Yale University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - BS in Chemistry and Biology
Massachusetts Institute of Technology (MIT)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - Internal medicine
cardiology, and cardiac electrophysiology training, Yale University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- Chair
Scientific Programs Committee, Cardiac Safety Research Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗ - Executive Committee member
Cardiac Safety Research Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - ICH Expert Working Group PhRMA Topic Leader
QT interval regulatory guidance (ICH E14)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Awards & honors
honors on the public record- Fellow
American College of Cardiology (FACC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - Fellow
American Heart Association (FAHA)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - Fellow
Heart Rhythm Society (FHRS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗
Secondary affiliations
appointments beyond the home institution- Chief Medical Advisor
Milestone Pharmaceuticals
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - Member
Board of Directors, Anthera Pharmaceuticals
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →milestonepharma.com ↗ - Former tenured faculty member
Cardiology, UCLA School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University School of Medicine
Alan Schatzberg, MD
Stanford University School of Medicine
Mark Pegram, MD
Stanford University School of Medicine
Vibeke Strand, MD
Stanford University School of Medicine